Abstract
NK cells are bone marrow-derived cytotoxic lymphocytes that play a major role in the rejection of tumors and cells infected by viruses. The regulation of NK activation vs inhibition is regulated by the expression of a variety of NK receptors (NKRs) and specific NKRs’ ligands expressed on their targets. However, factors limiting NK therapy include small numbers of active NK cells in unexpanded peripheral blood and lack of specific tumor targeting. Chimeric antigen receptors (CAR) usually include a single-chain Fv variable fragment from a monoclonal antibody, a transmembrane hinge region, and a signaling domain such as CD28, CD3-zeta, 4-1BB (CD137), or 2B4 (CD244) endodimers. Redirecting NK cells with a CAR will circumvent the limitations of the lack of NK targeting specificity. This chapter focuses on the methods to expand human NK cells from peripheral blood by co-culturing with feeder cells and to modify the expanded NK cells efficiently with the in vitro transcribed CAR mRNA by electroporation and to test the functionality of the CAR-modified expanded NK cells for use in adoptive cellular immunotherapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Paust S, von Andrian UH (2011) Natural killer cell memory. Nat Immunol 12:500–508
Vivier E, Raulet DH, Moretta A et al (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44–49. doi:10.1126/science.1198687
Vivier E, Tomasello E, Baratin M et al (2008) Functions of natural killer cells. Nat Immunol 9:503–510. doi:10.1038/ni1582
Raulet DH, Vance RE (2006) Self-tolerance of natural killer cells. Nat Rev Immunol 6:520–531. doi:10.1038/nri1863
Shereck E, Satwani P, Morris E et al (2007) Human natural killer cells in health and disease. Pediatr Blood Cancer 49:615–623. doi:10.1002/pbc.21158
Fauriat C, Just-Landi S, Mallet F et al (2007) Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109:323–330. doi:10.1182/blood-2005-08-027979
Verheyden S, Bernier M, Demanet C (2004) Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 18:2002–2007. doi:10.1038/sj.leu.2403525
Imai C, Iwamoto S, Campana D (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106:376–383. doi:10.1182/blood-2004-12-4797
Chu Y, Hochberg J, Yahr A et al (2015) Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice. Cancer Immunol Res 3:333–344. doi:10.1158/2326-6066.CIR-14-0114
Denman CJ, Senyukov VV, Somanchi SS et al (2012) Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 7:e30264. doi:10.1371/journal.pone.0030264
Eshhar Z, Waks T, Gross G et al (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 90:720–724
Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733. doi:10.1056/NEJMoa1103849
Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509–1518. doi:10.1056/NEJMoa1215134
Brentjens RJ, Davila ML, Riviere I et al (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra138. doi:10.1126/scitranslmed.3005930
Kochenderfer JN, Dudley ME, Feldman SA et al (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709–2720. doi:10.1182/blood-2011-10-384388
Ruggeri L, Capanni M, Urbani E et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097–2100. doi:10.1126/science.1068440
Smyth MJ, Hayakawa Y, Takeda K et al (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2:850–861. doi:10.1038/nrc928
Degli-Esposti MA, Smyth MJ (2005) Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 5:112–124. doi:10.1038/nri1549
Ayello J, van de Ven C, Cairo E et al (2009) Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Exp Hematol 37:1216–1229. doi:10.1016/j.exphem.2009.07.009
Czuczman MS, Olejniczak S, Gowda A et al (2008) Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 14:1561–1570. doi:10.1158/1078-0432.CCR-07-1254, 14/5/1561 [pii]
Alter G, Malenfant JM, Altfeld M (2004) CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294:15–22. doi:10.1016/j.jim.2004.08.008, S0022-1759(04)00292-3 [pii]
Schuerwegh AJ, Stevens WJ, Bridts CH et al (2001) Evaluation of monensin and brefeldin A for flow cytometric determination of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha in monocytes. Cytometry 46:172–176. doi:10.1002/cyto.1102 [pii]
Acknowledgements
The authors thank Erin Morris, RN, for her excellent assistance with the preparation of this manuscript. The authors also thank Dr. Dario Campana (St. Jude Children’s Research Hospital) and Dr. Terrence Geiger (St. Jude Children’s Research Hospital) for kindly providing anti-CD20 scFv. The research for this study was supported by the grant from the Pediatric Cancer Research Foundation and the New York Medical College Intramural Research Award.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Chu, Y., Flower, A., Cairo, M.S. (2016). Modification of Expanded NK Cells with Chimeric Antigen Receptor mRNA for Adoptive Cellular Therapy. In: Somanchi, S. (eds) Natural Killer Cells. Methods in Molecular Biology, vol 1441. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3684-7_18
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3684-7_18
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3682-3
Online ISBN: 978-1-4939-3684-7
eBook Packages: Springer Protocols